View in EDS HTML Full Text PDF Full Text

Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models.

Saved in:
Bibliographic Details
Title: Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models.
Authors: Li Y; Loxo Oncology at Lilly, Eli Lilly and Company, New York City, New York, United States of America., Amaladas N; Loxo Oncology at Lilly, Eli Lilly and Company, New York City, New York, United States of America., O'Mahony M; Loxo Oncology at Lilly, Eli Lilly and Company, New York City, New York, United States of America., Manro JR; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America., Inigo I; Loxo Oncology at Lilly, Eli Lilly and Company, New York City, New York, United States of America., Li Q; Loxo Oncology at Lilly, Eli Lilly and Company, New York City, New York, United States of America., Rasmussen ER; Lilly Research Laboratories, Eli Lilly and Company, New York City, New York, United States of America., Brahmachary M; Lilly Research Laboratories, Eli Lilly and Company, New York City, New York, United States of America., Doman TN; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America., Hall G; Loxo Oncology at Lilly, Eli Lilly and Company, New York City, New York, United States of America., Kalos M; Lilly Research Laboratories, Eli Lilly and Company, New York City, New York, United States of America., Novosiadly R; Lilly Research Laboratories, Eli Lilly and Company, New York City, New York, United States of America., Puig O; Lilly Oncology, Alexandria Center for Life Sciences, New York City, New York, United States of America., Pytowski B; Loxo Oncology at Lilly, Eli Lilly and Company, New York City, New York, United States of America., Schaer DA; Loxo Oncology at Lilly, Eli Lilly and Company, New York City, New York, United States of America.
Source: PloS one [PLoS One] 2022 Jul 18; Vol. 17 (7), pp. e0268244. Date of Electronic Publication: 2022 Jul 18 (Print Publication: 2022).
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35849586
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Li+Y%22">Li Y</searchLink>; Loxo Oncology at Lilly, Eli Lilly and Company, New York City, New York, United States of America.<br /><searchLink fieldCode="AU" term="%22Amaladas+N%22">Amaladas N</searchLink>; Loxo Oncology at Lilly, Eli Lilly and Company, New York City, New York, United States of America.<br /><searchLink fieldCode="AU" term="%22O'Mahony+M%22">O'Mahony M</searchLink>; Loxo Oncology at Lilly, Eli Lilly and Company, New York City, New York, United States of America.<br /><searchLink fieldCode="AU" term="%22Manro+JR%22">Manro JR</searchLink>; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America.<br /><searchLink fieldCode="AU" term="%22Inigo+I%22">Inigo I</searchLink>; Loxo Oncology at Lilly, Eli Lilly and Company, New York City, New York, United States of America.<br /><searchLink fieldCode="AU" term="%22Li+Q%22">Li Q</searchLink>; Loxo Oncology at Lilly, Eli Lilly and Company, New York City, New York, United States of America.<br /><searchLink fieldCode="AU" term="%22Rasmussen+ER%22">Rasmussen ER</searchLink>; Lilly Research Laboratories, Eli Lilly and Company, New York City, New York, United States of America.<br /><searchLink fieldCode="AU" term="%22Brahmachary+M%22">Brahmachary M</searchLink>; Lilly Research Laboratories, Eli Lilly and Company, New York City, New York, United States of America.<br /><searchLink fieldCode="AU" term="%22Doman+TN%22">Doman TN</searchLink>; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America.<br /><searchLink fieldCode="AU" term="%22Hall+G%22">Hall G</searchLink>; Loxo Oncology at Lilly, Eli Lilly and Company, New York City, New York, United States of America.<br /><searchLink fieldCode="AU" term="%22Kalos+M%22">Kalos M</searchLink>; Lilly Research Laboratories, Eli Lilly and Company, New York City, New York, United States of America.<br /><searchLink fieldCode="AU" term="%22Novosiadly+R%22">Novosiadly R</searchLink>; Lilly Research Laboratories, Eli Lilly and Company, New York City, New York, United States of America.<br /><searchLink fieldCode="AU" term="%22Puig+O%22">Puig O</searchLink>; Lilly Oncology, Alexandria Center for Life Sciences, New York City, New York, United States of America.<br /><searchLink fieldCode="AU" term="%22Pytowski+B%22">Pytowski B</searchLink>; Loxo Oncology at Lilly, Eli Lilly and Company, New York City, New York, United States of America.<br /><searchLink fieldCode="AU" term="%22Schaer+DA%22">Schaer DA</searchLink>; Loxo Oncology at Lilly, Eli Lilly and Company, New York City, New York, United States of America.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101285081%22">PloS one</searchLink> [PLoS One] 2022 Jul 18; Vol. 17 (7), pp. e0268244. <i>Date of Electronic Publication: </i>2022 Jul 18 (<i>Print Publication: </i>2022).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Public+Library+of+Science%22">Public Library of Science </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101285081 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>1932-6203 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2219326203%22">19326203 </searchLink><i>NLM ISO Abbreviation: </i>PLoS One <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35849586
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1371/journal.pone.0268244
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e0268244
    Titles:
      – TitleFull: Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Li Y
      – PersonEntity:
          Name:
            NameFull: Amaladas N
      – PersonEntity:
          Name:
            NameFull: O'Mahony M
      – PersonEntity:
          Name:
            NameFull: Manro JR
      – PersonEntity:
          Name:
            NameFull: Inigo I
      – PersonEntity:
          Name:
            NameFull: Li Q
      – PersonEntity:
          Name:
            NameFull: Rasmussen ER
      – PersonEntity:
          Name:
            NameFull: Brahmachary M
      – PersonEntity:
          Name:
            NameFull: Doman TN
      – PersonEntity:
          Name:
            NameFull: Hall G
      – PersonEntity:
          Name:
            NameFull: Kalos M
      – PersonEntity:
          Name:
            NameFull: Novosiadly R
      – PersonEntity:
          Name:
            NameFull: Puig O
      – PersonEntity:
          Name:
            NameFull: Pytowski B
      – PersonEntity:
          Name:
            NameFull: Schaer DA
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 18
              M: 07
              Text: 2022 Jul 18
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1932-6203
          Numbering:
            – Type: volume
              Value: 17
            – Type: issue
              Value: 7
          Titles:
            – TitleFull: PloS one
              Type: main
ResultId 1